As a pediatrician I am very familiar with respiratory syncytial virus (RSV). In infants and young children RSV infection results in a sometimes frightening seasonal illness called bronchiolitis. The virus affects the smallest airways, called the bronchioles, and results in wheezing and trouble breathing. There is no effective antiviral medication, only supportive treatment. The illness is especially severe in premature infants. In June 1998 one of the first monoclonal antibody drugs palivizumab was approved as a preventative measure given to premature infants at high risk for severe infection. In July 2023 another monoclonal antibody drug named nirsevimab-alip was approved for […]